Quick Links: Skip to main page content Skip to Search Skip to Topics Menu Skip to Common Links
  • Decrease font size
  • Return font size to normal
  • Increase font size
U.S. Department of Health and Human Services

Search Orphan Drug Designations and Approvals
  • Print
  • Share
  • E-mail
-
Generic Name: rituximab
Trade Name: Rituxan(r); MabThera(r)
Date Designated: 02/23/2015
Orphan Designation: Treatment of pemphigus vulgaris.
Orphan Designation Status: Designated/Approved
Genentech, Inc.
1 DNA Way
South San Francisco, California 94080
United States

The sponsor address listed is the last reported by the sponsor to OOPD.

Marketing approved:

1 Generic Name: rituximab
Trade Name: Rituxan(r); MabThera(r)
Marketing Approval Date: 06/07/2018
Approved Labeled Indication: RITUXAN is indicated for the treatment of adult patients with moderate to severe pemphigus vulgaris.
Exclusivity End Date: 06/07/2025 
Exclusivity Protected Indication* :  RITUXAN is indicated for the treatment of adult patients with moderate to severe pemphigus vulgaris.
*Exclusivity Protected Indications are shown for approvals from 01/01/2013 to the present.
*Data for the Date Designation Withdrawn or Revoked field are shown for designations withdrawn or revoked after 08/12/2013.
-
-